Topper James N

Director Topper James N bought 660 shares of NAMS at $23.70; 5 prior buys show 90d returns from +7.3% to +29.2%.

Topper James N, a director holding 3,028,524 shares, purchased 660 shares at $23.70 on 2025-09-15, adding to a pattern of repeated buying at this ticker over the past three months. His prior four measurable trades at NAMS all posted positive 90-day returns, with the most recent showing +24.1% and earlier purchases returning +7.3%, +26.9%, and +29.2%. This cadence of incremental accumulation, combined with strong historical execution at this specific ticker, contrasts with the company's present fundamentals: NewAmsterdam Pharma is unprofitable (full-year net income was negative, latest quarter showing $-17,364,000.00), though revenue grew sharply at +223.4% year-over-year. The stock has retreated -3.6% over the past 30 days from its -9.3% distance below the 52-week high of $27.00, placing this buy near recent lows relative to recent range. An investor should track whether this repeated buying pattern persists and whether the company's trajectory toward profitability matches the director's apparent conviction reflected in his purchase frequency.

Director Topper James N bought 1,260 shares of NAMS at $24.99 on 2025-09-08, continuing a pattern of recent accumulation in unprofitable biotech.

Topper James N purchased 1,260 shares at $24.99, adding to a position of 3.03M shares with minimal impact on his overall holdings (+0.0% vs pre-transaction). His prior open-market history across all tickers shows 13 buys with a 66.67% 90-day win rate and average +9.4% 90-day return, suggesting some predictive value to his purchase decisions. At NAMS specifically, he has made 5 prior trades in 2025, including buys on 2025-08-11, 2025-06-25, 2025-06-24, and 2025-06-16, though only one (2025-03-26) has a completed 90-day outcome of -18.2%, indicating zero well-timed buys at the 90-day mark at this ticker. The company reported revenue of $19,145,000.00 (latest quarter) and net income of -$17,364,000.00, underscoring ongoing unprofitability; however, annual revenue growth was +223.4%, reflecting early-stage biotech scale-up typical of high-growth, pre-profitable companies. The current price of $26.90 sits 0.4% below the 52-week high and is +10.4% over 30 days, providing context for the director's open-market purchases, though the pattern of frequent accumulation in an unprofitable entity warrants attention to both company milestones and any clinical or regulatory developments.

Director Topper James N bought 471 shares of NAMS at $23.98 on 2025-08-11, raising holdings to 3.03M shares

Director Topper James N purchased 471 shares at $23.98, a modest addition to an already substantial 3.03M-share position. The purchase price sits 6.9% below the current price of $25.76, and the stock has appreciated 16.2% over the prior 30 days and 37.8% over the prior 90 days. However, prior trades at NAMS reveal mixed outcomes: his two most recent purchases (2025-06-25 and 2025-06-24) show strong 30-day returns of +29.2% and +26.9% respectively, but earlier purchases in March showed negative 90-day returns of -18.2% and -10.0%. The company remains unprofitable with net income of $-17.4M against quarterly revenue of $19.1M, though it is growing rapidly with annual revenue growth of +223.4%. The modest size of this transaction relative to existing holdings suggests incremental accumulation rather than a significant directional signal.

Director Topper James N bought 3,780 shares (3.8K shares) of NAMS for $69,466.07 in two transactions on 2025-06-24 and 2025-06-25

James N Topper, a Director at NewAmsterdam Pharma, executed two separate purchases totaling 3,780 shares at a blended average price of $18.38 on June 24-25, 2025, adding 0.1% to his existing 3.02M share position. The stock currently trades at $18.45, near the transaction prices but notably 30.7% below its 52-week high of $26.61 and down 15.2% over the past 90 days despite a recent 8.5% 30-day gain. Examining his prior trades at NAMS reveals a pattern of unsuccessful timing: his 3 prior measurable purchases at this ticker (March 4, March 26, and April 2024) all posted negative 90-day returns ranging from -0.3% to -22.1%, with a 0.00% well-timed rate at the 90-day mark. While the company reports strong annual revenue growth of 223.4%, it remains deeply unprofitable with a net loss of $39.5M against quarterly revenue of $3.0M, raising questions about the sustainability of that growth trajectory. This purchase occurs in an unfavorable risk/reward context: the stock is well below its peak, the insider has demonstrated poor prior timing at this exact ticker, and the underlying business fundamentals remain challenged despite expansion.

Director Topper James N buys 8,584 shares of NAMS at $19.50; stock now -31.6% from 52-week high, -24.4% over 90 days.

Topper James N purchased 8,584 shares (8.6K shares) of NewAmsterdam Pharma at $19.50 on 2025-06-16 for $167,381.13, increasing his holdings to 3.02M shares. The timing is noteworthy: the stock has fallen -24.4% over 90 days and is -31.6% below its 52-week high of $26.61, currently at $18.20. Examining his same-ticker history reveals a pattern of misfortune: his prior two measurable buys at NAMS (2025-03-04 and 2024-03-26) both declined over 90 days (-10.0% and -8.7%, respectively), with a 0% win rate at the 90-day mark. His cross-ticker track record shows 9 prior open-market buys with a 0.00% 90-day win rate and an average 90-day return of -9.3%, suggesting a consistent pattern of entering positions that subsequently decline. The company remains unprofitable ($-39.5M net income over the latest fiscal period despite 223.4% annual revenue growth), adding fundamental uncertainty to what already appears as a directionally challenged insider purchase sequence.

Director Topper James N acquired 3,780 shares of PHAT at $3.86 on 2025-05-21; stock now -79.4% from 52-week high at $4.02 current price

Director Topper James N purchased 3,780 shares at $3.86 on 2025-05-21, increasing his holdings from 55.6K to 59.4K shares. This marks the fifth consecutive buy in five business days, all at PHAT. The stock trades at $4.02, which is -79.4% from the 52-week high of $19.50 and -29.1% lower over the past 90 days. The insider's cross-ticker track record shows 8 prior open-market buys with a 0.00% 90-day win rate, an average 90-day return of -8.7%, and prior buys averaging -12.2% over 30 days. The company is unprofitable (net income of $-94.3M on quarterly revenue of $28.5M) despite 8001.5% annual revenue growth, suggesting significant losses on a dramatically expanded revenue base. The rapid, sequential accumulation at a depressed price without measurable outcomes from prior same-ticker trades raises questions about timing quality and underlying valuation signals.

Director James Topper bought 7,420 shares across 2 transactions for $24,462.49 at PHAT, raising stake 15.4% to 55,623 shares

Director James Topper made 2 separate purchases totaling 7,420 shares for $24,462.49 on May 13–14, 2025, at prices of $3.16 and $3.32—just below the current price of $3.48. The purchases raised his holdings by 15.4% to 55,623 shares. However, this activity occurs within a severely depressed valuation context: the stock is -82.2% from its 52-week high of $19.50 and down -27.0% over 30 days and -39.7% over 90 days. Across his open-market trading history, Topper's track record shows 6 prior buys with an average 90-day return of -8.7% and a 0.00% win rate, suggesting his prior purchase timing has not delivered gains. At PHAT specifically, he has made 3 prior purchases in early May 2025 with outcomes not yet measurable. The company is unprofitable with a net loss of $-94,316,000.00 in the latest quarter and an annual revenue growth of +8001.5%, reflecting recent corporate restructuring or status changes. The combination of significant new investment by a director amid sharp recent price declines, coupled with his historically poor buy-timing record and the company's unprofitability, merits investor attention but does not constitute clear confirmation of near-term opportunity.

Director Topper James N bought 48,203 shares ($152.9K) at average $3.17, now trading -83.0% from 52-week high of $19.50

Director Topper James N executed 3 separate purchases totaling 48,203 shares for $152,916.63 across two trading days in mid-May, establishing an initial position at a blended average price of $3.17. The current price of $3.31 reflects minimal post-purchase movement, though the stock has declined 32.2% over the prior 30 days and 39.6% over 90 days, trading at 83.0% below its 52-week high of $19.50. Phathom remains unprofitable with a net loss of $94,316,000.00 against quarterly revenue of $28,519,000.00, and the director's own cross-ticker buy history shows zero 90-day wins with an average 90-day return of -8.7%, providing limited confidence that this entry point will prove prescient as market conditions continue to deteriorate.

Director Topper buys 1,135 shares of NAMS at $22.49; stock now $21.76, -18.2% from 52-week high.

Director James N Topper purchased 1,135 shares at $22.49 on 2025-03-26, bringing his post-transaction holdings to 3,013,569 shares. The stock has declined to $21.76 since the purchase and sits -18.2% from its 52-week high, though it is up 10.4% over the past 30 days. This is Topper's second purchase within the past month at NAMS (a prior buy on 2025-03-04 is also recorded), suggesting repeated accumulation at current levels. However, his track record across all tickers shows 0 of 1 prior buys were well-timed at the 90-day mark, with a cross-ticker average 90-day return of -8.7%, providing limited confidence that this recent acquisition will outperform. The company remains unprofitable on a full-year basis despite strong annual revenue growth of +223.4%, introducing execution and cash-burn risk that investors should monitor.

Director Topper buys 4,005 shares of NAMS at $21.02 on 2025-03-04; mixed signal given poor prior timing at same ticker.

Topper James N, a Director, purchased 4,005 shares of NewAmsterdam Pharma at $21.02 on 2025-03-04, adding a small increment to his 3.01M share holdings. The timing context is unfavorable: his sole prior buy at NAMS on 2024-03-26 returned -8.7% over 90 days, and his cross-ticker track record shows 0 of 1 prior buys were well-timed at the 90-day mark with an average 90d return of -8.7%. The company is unprofitable with a -$16.6M net income on $29.1M revenue in the latest quarter, though it reports strong annual growth of +223.4%. Current price is $23.50, representing a modest gain of 11.9% from the purchase price but still -11.7% from the 52-week high. This purchase does not establish conviction given the insider's historical execution pattern at this specific security.